RET fusions are also a rare condition in CCA (up to 0.15%).234 In the phase I/II ARROW trial, pralsetinib, a selective inhibitor of RET, was evaluated in RET fusion-positive patients. The gene discussed is RET; the disease is cholangiocarcinoma.